<!--StartFragment-->
 1. Bates G., Tabrizi S., Jones L. Huntington’s disease / G. Bates, S. Tabrizi, L. Jones, Oxford University Press (UK), 2014. 

 2. Bates G.P. et al. Huntington disease // Nature Reviews Disease Primers. 2015. (1). C. 15005. 

 3. Kay C. et al. Huntington disease reduced penetrance alleles occur at high frequency in the general population // Neurology. 2016. ¹ 3 (87). C. 282–288. 

 4. Killoran A., Biglan K.M. Current therapeutic options for Huntington’s disease: Good clinical practice versus evidence-based approaches? // Movement disorders. 2014. ¹ 11 (29). C. 1404–1413. 

 5. Kivela J.E. et al. Anesthetic Management of Patients with Huntington Disease // Anesthesia & Analgesia. 2010. ¹ 2 (110). C. 515–523. 

 6. Nance M. et al. A Physician’s Guide to the Management of Huntington’s Disease // 2011. 

 7. Pringsheim T. et al. The incidence and prevalence of Huntington’s disease: A systematic review and meta-analysis // Movement disorders. 2012. ¹ 9 (27). C. 1083–1091. 

 8. Rawlins M.D. et al. The Prevalence of Huntington’s Disease // Neuroepidemiology. 2016. ¹ 2 (46). C. 144–153. 

 9. Reilmann R., Leavitt B.R., Ross C.A. Diagnostic criteria for Huntington’s disease based on natural history // Movement disorders. 2014. ¹ 11 (29). C. 1335–1341. 

 10. Shoulson I. et al. Assessment of functional capacity in neurodegenerative movement disorders: Huntington’s disease as a prototype // Quantification of neurologic deficit. Boston: Butterworths. 1989. C. 271–283. 

 11. Genetic testing in asymptomatic minors: recommendations of the European Society of Human Genetics // European Journal of Human Genetics. 2009. ¹ 6 (17). C. 720–721. 

 12. D?sam?ricq G., et al. Guidelines for clinical pharmacological practices in Huntington"s disease // Revue Neurologique. 2016. ¹ 8-9 (172). Ñ. 423–432. 
<!--EndFragment-->